Etiology and Risk Factors in Patients with Vulvovaginal Candidiasis in Abidjan (Côte d'Ivoire)

다국어 초록 (Multilingual Abstract)

Background: Limited data on the molecular identification of vulvovaginal candidiasis (VVC) pathogenesis in Côte d'Ivoire are available.
Objective: We sought to update the data on the causes of VVC in Abidjan, Côte d'Ivoire.
Methods: Conducted between May 2023 and January 2024, this cross-sectional study focused on patients with symptoms suggestive of VVC in Abidjan. Each patient underwent swab collection, direct examination, and culture.
Candida chromatic agar and Auxacolor®-based identification tests were performed. A molecular-based polymerase chain reaction (PCR) targeting the hyphal wall protein 1 (hwp1) gene was used to differentiate between C. albicans, C. africana, and C. dubliniensis.
Results: The overall prevalence of fungal VVC was 53.6% (222/414 patients). After PCR, no C. africana or C.
dubliniensis were observed. C. albicans isolates exhibited two PCR profiles: 941 bp and 941+850 bp, with C.
albicans being the most frequently isolated species (70.7%) after C. tropicalis (9.9%). The most affected groups were patients younger than 25 (p = 0.018), those living in precarious housing (p < 0.0001), and pregnant women (p = 0.006). In addition, the presence of vulvovaginal candidiasis was significantly associated with vaginal irrigation (i.e., douching) frequency (p = 0.003), douche used (e.g., antibacterial or not) (p = 0.003), and underwear type (p = 0.037). The most common symptom reported was vaginal itching (46.4%).
Conclusion: No strains of C. africana and C. dubliniensis were found. The increased prevalence of VVC in Abidjan warrants further studies.

참고문헌 (Reference)

• 1 Sustr V, "Vulvovaginal candidosis : current concepts, challenges and perspectives" 6 : 267-, 2020
• 2 Aguin TJ, "Vulvovaginal candidiasis in pregnancy" 17 : 30-, 2015
• 3 Pereira LC, "Vulvovaginal candidiasis and current perspectives : new risk factors and laboratory diagnosis by using MALDI TOF for identifying species in primary infection and recurrence" 40 : 1681-1693, 2021
• 4 Bitew A, "Vulvovaginal candidiasis : species distribution of Candida and their antifungal susceptibility pattern" 18 : 94-, 2018
• 5 Nyirjesy P, "Vulvovaginal candidiasis" 30 : 671-684, 2003
• 6 Rezazadeh E, "Use of costeffective and rapid molecular tools for identification of Candida species, opportunistic pathogens" 2 : 1-4, 2016
• 7 Cooke G, "Treatment for recurrent vulvovaginal candidiasis(thrush)" 1 : CD009151-, 2022
• 8 Phillips NA, "Topical treatment of recurrent vulvovaginal candidiasis : an expert consensus" 3 : 38-42, 2022
• 9 Jackson ST, "The epidemiology of mycotic vulvovaginitis and the use of antifungal agents in suspected mycotic vulvovaginitis and its implications for clinical practice" 54 : 192-195, 2005
• 10 Angora KE, "Susceptibility of Candida species isolated from recurrent vulvovaginal candidiasis to antifungal agents among women at Institut Pasteur of Côte d'Ivoire" 9 : 21-26, 2018
• 11 Jeanmonod R, "StatPearls" StatPearls Publishing 2023
• 12 Djohan V, "Sensibilité in vitro des souches de Candida albicans d'origine vaginale aux antifongiques àAbidjan(Côte d'Ivoire)" 22 : 129-133, 2012
• 13 Djohan V, "Recurrent vulvovaginal candidiasis in Abidjan(Côte d'Ivoire) : Aetiology and associated factors" 29 : 127-131, 2019
• 14 Sobel JD, "Recurrent vulvovaginal candidiasis" 214 : 15-21, 2016
• 15 Kalia N, "Prevalence of vulvovaginal infections and species-specific distribution of vulvovaginal candidiasis in married women of North India" 4 : 253-266, 2015
• 16 Foxman B, "Prevalence of recurrent vulvovaginal candidiasis in 5European countries and the United States : results from an internet panel survey" 17 : 340-345, 2013
• 17 Grigoriou O, "Prevalence of clinical vaginal candidiasis in a university hospital and possible risk factors" 126 : 121-125, 2006
• 18 Disha T, "Prevalence and risk factors of vulvovaginal candidosis during pregnancy : a review" 2022 : 6195712-, 2022
• 19 de Leon EM, "Prevalence and risk factors for vaginal Candida colonization in women with type 1 and type 2 diabetes" 2 : 1-, 2002
• 20 Kunzelmann V, "Prerequisites for effective therapy of chronic recurrent vaginal candidiasis" 39 (39): 65-72, 1996
• 21 Odds FC, "Molecular phylogenetics of Candida albicans" 6 : 1041-1052, 2007
• 22 Charsizadeh A, "Microbial epidemiology of candidaemia in neonatal and paediatric intensive care units at the Children's Medical Center, Tehran" 61 : 22-29, 2018
• 23 Amouri I, "La candidose vulvovaginale : revue" 20 : 108-115, 2010
• 24 Benchellal M, "La candidose vulvo-vaginale àl'hôpital militaire d'instruction Mohammed V(Maroc)" 21 : 106-112, 2011
• 25 Sharifynia S, "In vitro antifungal susceptibility profiles of Candida albicans complex isolated from patients with respiratory infections" 54 : 376-381, 2016
• 26 Dieng Y, "Identification de trois souches de Candida africana au Sénégal" 22 : 335-340, 2012
• 27 Ngouana TK, "Genetic diversity of the Hwp1 gene and HIS3, EF3, CDC3 microsatellites and antifungal susceptibility profiles of Candida albicans isolates from Yaoundé HIV-infected patients" 55 : 546-554, 2017
• 28 Romeo O, "First molecular method for discriminating between Candida africana, Candida albicans, and Candida dubliniensis by using hwp1 gene" 62 : 230-233, 2008
• 29 Butler G, "Evolution of pathogenicity and sexual reproduction in eight Candida genomes" 459 : 657-662, 2009
• 30 Anderson MR, "Evaluation of vaginal complaints" 291 : 1368-1379, 2004
• 31 Borman AM, "Epidemiology, antifungal susceptibility, and pathogenicity of Candida africana isolates from the United Kingdom" 51 : 967-972, 2013
• 32 Pfaller MA, "Epidemiology of invasive candidiasis : a persistent public health problem" 20 : 133-163, 2007
• 33 Gharehbolagh SA, "Distribution, antifungal susceptibility pattern, and intra-Candida albicans species complex prevalence of Candida africana : A systematic review and meta-analysis" 15 : e0237046-, 2020
• 34 Sullivan DJ, "Candida dubliniensis sp. nov. : phenotypic and molecular characterization of a novel species associated with oral candidosis in HIV-infected individuals" 141 (141): 1507-1521, 1995
• 35 Loreto ES, "Candida dubliniensis : epidemiology and phenotypic methods for identification" 169 : 431-443, 2010
• 36 Tietz HJ, "Candida africana sp. nov., a new human pathogen or a variant of Candida albicans?" 44 : 437-445, 2001
• 37 Romeo O, "Candida africana and its closest relatives" 54 : 475-486, 2011
• 38 Nikmanesh B, "Candida africana and Candida dubliniensis as causes of pediatric candiduria : A study using HWP1 gene size polymorphism" 6 : 272-279, 2020
• 39 Chassot F, "Can intrauterine contraceptive devices be a Candida albicans reservoir?" 77 : 355-359, 2008
• 40 Richter SS, "Antifungal susceptibilities of Candida species causing vulvovaginitis and epidemiology of recurrent cases" 43 : 2155-2162, 2005
• 41 Makanjuola O, "An update on the roles of non-albicans Candida species in vulvovaginitis" 4 : 121-, 2018
• 42 Konaté A, "Aetiologies and contributing factors of vulvovaginal candidiasis in Abidjan(Côte d'Ivoire)" 24 : 93-99, 2014